On June 12, 2025, Quince Therapeutics, Inc. entered into a Securities Purchase Agreement to raise approximately $11.5 million by selling 6.67 million shares and warrants to institutional investors and management. Key purchases included $200,000 by CEO Dirk Thye and other management contributions totaling $60,000.